South Dakota Investment Council lifted its holdings in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 7.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 121,181 shares of the company’s stock after purchasing an additional 8,883 shares during the period. Elevance Health comprises 0.7% of South Dakota Investment Council’s portfolio, making the stock its 20th largest holding. South Dakota Investment Council’s holdings in Elevance Health were worth $35,476,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. WealthCollab LLC raised its holdings in shares of Elevance Health by 42.2% in the first quarter. WealthCollab LLC now owns 91 shares of the company’s stock valued at $27,000 after buying an additional 27 shares during the last quarter. Kemnay Advisory Services Inc. bought a new stake in Elevance Health during the 4th quarter worth about $31,000. J.Safra Asset Management Corp bought a new stake in Elevance Health during the 4th quarter worth about $32,000. ORG Partners LLC increased its position in Elevance Health by 120.4% in the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after acquiring an additional 59 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in Elevance Health in the 4th quarter valued at about $38,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.
Elevance Health Stock Performance
Elevance Health stock opened at $376.21 on Thursday. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 0.68. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $436.24. The company has a market cap of $81.59 billion, a PE ratio of 16.72, a PEG ratio of 2.22 and a beta of 0.67. The company’s 50-day moving average is $397.65 and its two-hundred day moving average is $356.66.
Elevance Health Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be paid a $1.72 dividend. The ex-dividend date of this dividend is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. Elevance Health’s dividend payout ratio (DPR) is presently 30.58%.
Insider Transactions at Elevance Health
In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the sale, the director owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. The trade was a 1.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.34% of the company’s stock.
Key Headlines Impacting Elevance Health
Here are the key news stories impacting Elevance Health this week:
- Positive Sentiment: Zacks Research raised multiple earnings estimates. The firm increased its FY2026 EPS forecast to $27.06 from $26.79, FY2027 to $28.83 from $28.51, and FY2028 to $32.49 from $31.77. It also raised estimates for Q2 2027, Q4 2027, Q1 2028 and Q2 2028, indicating improving expectations for Elevance Health’s longer-term profitability.
- Positive Sentiment: Insider buying provided a vote of confidence. A report highlighted purchases of Elevance Health shares by the company’s CEO and chairman, a potentially supportive signal because insider buying can suggest management views the stock as undervalued. Elevance Health Pick of the Week at Smart Insider Following CEO, Chairman Share Purchases
- Neutral Sentiment: Peer comparison offers limited direct impact. A head-to-head survey compared Elevance Health with Aeon Global Health, but the article does not indicate a material change to ELV’s earnings outlook or valuation. Head to Head Survey: Elevance Health and Aeon Global Health
- Negative Sentiment: Analyst commentary remains cautious. A Seeking Alpha analysis said Elevance Health has upside potential but is “not yet a buy,” which may limit buying interest. Investors may also be focused on near-term earnings pressure: the latest quarterly EPS of $7.45 exceeded estimates but declined from $8.84 in the prior-year period. Elevance Health Has Upside, But Not Yet A Buy
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on the stock. Cantor Fitzgerald upped their target price on shares of Elevance Health from $400.00 to $450.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 7th. Wells Fargo & Company lowered their price target on shares of Elevance Health from $492.00 to $473.00 and set an “overweight” rating for the company in a report on Thursday, July 16th. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Raymond James Financial set a $450.00 price objective on Elevance Health in a report on Tuesday, July 7th. Finally, TD Cowen increased their price objective on Elevance Health from $400.00 to $465.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $440.90.
Get Our Latest Analysis on Elevance Health
Elevance Health Company Profile
Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.
Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.
Featured Stories
- Five stocks we like better than Elevance Health
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
